Insulet (PODD) Operating Expenses (2010 - 2026)

Insulet has reported Operating Expenses for 17 years, with the latest figure at $406.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 27.04% year-over-year to $406.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (up 28.62% YoY), and the FY2025 full-year result was $1.5 billion, up 28.97% from the prior year.
• Operating Expenses for Q1 2026 stood at $406.9 million, down from $422.3 million in the prior quarter.
• The five-year high for Operating Expenses was $422.3 million in Q4 2025, with the low at $171.8 million in Q1 2022.
• Historically, Operating Expenses has averaged $277.5 million across 5 years, with a median of $254.7 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 441.15% — and 2023, when it grew 7.74%.
• Insulet's Operating Expenses stood at $193.8 million in 2022, then surged by 31.42% to $254.7 million in 2023, then grew by 26.23% to $321.5 million in 2024, then surged by 31.35% to $422.3 million in 2025, then slipped by 3.65% to $406.9 million in 2026.
• The last three Operating Expenses figures came in at $406.9 million (Q1 2026), $422.3 million (Q4 2025), and $392.4 million (Q3 2025), per Business Quant data.